217 related articles for article (PubMed ID: 11950014)
1. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
[TBL] [Abstract][Full Text] [Related]
2. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.
Davas EM; Peppas C; Maragou M; Alvanou E; Hondros D; Dantis PC
Clin Rheumatol; 1999; 18(6):455-61. PubMed ID: 10638770
[TBL] [Abstract][Full Text] [Related]
3. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
4. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
5. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.
Silver RM; Miller KS; Kinsella MB; Smith EA; Schabel SI
Am J Med; 1990 May; 88(5):470-6. PubMed ID: 2337105
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
8. T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis.
Beretta L; Cappiello F; Barili M; Bertolotti F; Scorza R
Clin Rheumatol; 2007 Jan; 26(1):88-91. PubMed ID: 16636934
[TBL] [Abstract][Full Text] [Related]
9. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
13. Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease.
Arunsurat I; Mahakkanukrauh A; Foocharoen C; Suwannaroj S; Nanagara R;
Clin Rheumatol; 2021 Jan; 40(1):205-211. PubMed ID: 32519048
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
[TBL] [Abstract][Full Text] [Related]
15. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
16. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
17. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results.
Airò P; Danieli E; Parrinello G; Antonioli CM; Cavazzana I; Toniati P; Franceschini F; Cattaneo R
Clin Exp Rheumatol; 2004; 22(5):573-8. PubMed ID: 15485010
[TBL] [Abstract][Full Text] [Related]
18. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
[TBL] [Abstract][Full Text] [Related]
19. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis.
De Santis M; Bosello S; La Torre G; Capuano A; Tolusso B; Pagliari G; Pistelli R; Danza FM; Zoli A; Ferraccioli G
Respir Res; 2005 Aug; 6(1):96. PubMed ID: 16107215
[TBL] [Abstract][Full Text] [Related]
20. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.
Steen VD; Lanz JK; Conte C; Owens GR; Medsger TA
Arthritis Rheum; 1994 Sep; 37(9):1290-6. PubMed ID: 7945491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]